In this review we update the role of “non ABL-directed inhibitors” targeting signaling pathways downstream of the BCR-ABL1 oncoprotein and describe immunological approaches activating specific T cell responses against CML cells. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.